These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32476183)

  • 1. Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial.
    Bines J; Small IA; Sarmento R; Kestelman F; Silva S; Rodrigues FR; Faroni L; Gonçalves A; Ebecken E; Maroun P; Millen E; Bonamino M
    Oncologist; 2020 Sep; 25(9):758-764. PubMed ID: 32476183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
    Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
    Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
    Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
    Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
    Estévez LG; Gradishar WJ
    Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.
    Wang C; Yuan L; Wu X; Wang Y; Tian H; Zhang G; Wan A; Xiong S; Wang C; Zhou Y; Ma D; Bao Y; Qu M; Jiang J; Zhang Y; Qi X
    BMC Med; 2024 Jun; 22(1):252. PubMed ID: 38886794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
    D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
    Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
    Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
    PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
    Bonnefoi H; Piccart M; Bogaerts J; Mauriac L; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Blot E; Zaman K; Cufer T; Lortholary A; Lidbrink E; André S; Litière S; Lago LD; Becette V; Cameron DA; Bergh J; Iggo R;
    Lancet Oncol; 2011 Jun; 12(6):527-39. PubMed ID: 21570352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    ;
    Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
    Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
    Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008-2012.
    Hannouf M; Batra A; Lupichuk S
    Curr Oncol; 2021 Mar; 28(2):1137-1142. PubMed ID: 33806441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.
    Lim B; Song J; Ibrahim NK; Koenig KB; Chavez-MacGregor M; Ensor JE; Gomez JS; Krishnamurthy S; Caudle AS; Shaitelman SF; Whitman GJ; Valero V
    Oncologist; 2021 Feb; 26(2):e230-e240. PubMed ID: 33140515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer.
    Anand K; Niravath P; Patel T; Ensor J; Rodriguez A; Boone T; Wong ST; Chang JC
    Clin Breast Cancer; 2021 Jun; 21(3):199-204. PubMed ID: 34159901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
    Yang H; Xu L; Guan S; Hao X; Ge Z; Tong F; Cao Y; Liu P; Zhou B; Cheng L; Liu M; Liu H; Xie F; Wang S; Peng Y; Wang C; Wang S
    BMC Cancer; 2022 Dec; 22(1):1357. PubMed ID: 36577958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer.
    Chen W; Tu Q; Shen Y; Tang K; Hong M; Shen Y
    World J Surg Oncol; 2021 Feb; 19(1):52. PubMed ID: 33602236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis.
    Giffoni de Mello Morais Mata D; Rush MB; Smith-Uffen M; Younus J; Lohmann AE; Trudeau M; Morgan RL
    Curr Oncol; 2024 Aug; 31(8):4486-4506. PubMed ID: 39195318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
    Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
    Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.